Regulus Therapeutics Announces Expected Addition To The Russell 3000 And Russell 2000 Indexes

6/4/24 8:13:04 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $RGLS alert in real time by email

Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it expects to be added to the broad-market Russell 3000® Index and the Russell 2000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th.

Get the next $RGLS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RGLS

Date	Price Target	Rating	Analyst
8/2/2024	$7.00	Outperform	Oppenheimer
3/18/2024	$6.00	Outperform	Leerink Partners
9/2/2021	$2.00	Overweight	Cantor Fitzgerald

More analyst ratings

$RGLS
Press Releases

Fastest customizable press release news feed in the world

Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates
Completed enrollment in the fourth cohort of the Phase 1b multiple-ascending dose (MAD) clinical trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Presented a poster highlighting data from the ongoing MAD study of RGLS8429 in ADPKD at American Society of Nephrology (ASN) Kidney Week On track for an End-of-Phase 1 meeting by year-end Ended third quarter 2024 with cash, cash equivalents, and investments of $87.3 million; Cash runway into H1 2026 SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company"
11/7/24 4:05:00 PM ET
$RGLS
Biotechnology: Pharmaceutical Preparations
Health Care
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
SAN DIEGO, Oct. 8, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced it has completed enrollment of 26 patients in the fourth cohort in the Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. "The completion of enrollment of our final cohort marks an important milestone as we near the end of our Phase 1b study. We have been pleased to see positive results from each of the prior three cohorts, showing c
10/8/24 8:00:00 AM ET
$RGLS
Biotechnology: Pharmaceutical Preparations
Health Care
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
SAN DIEGO, Aug. 28, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will participate in the following investor conferences: Wells Fargo Healthcare Conference: Fireside chat on Wednesday, September 4, 2024, at 2:15 p.m. ETH.C. Wainwright 26th Annual Global Investment Conference: Fireside chat on Monday, September 9, 2024, at 10:00 a.m. ETThe live events and replays of the presentations will
8/28/24 8:00:00 AM ET
$RGLS
Biotechnology: Pharmaceutical Preparations
Health Care

$RGLS
Financials

Live finance-specific insights

Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Continued mechanistic dose response observed following completion of 3 mg/kg dose level based on urinary biomarker analyses Percent change from baseline in PC1 and PC2 demonstrated a dose response across all doses tested, with statistical significance seen at 3 mg/kg compared to placebo Exploratory imaging analyses indicated reduction in total kidney volume in 70% of patients dosed with 3 mg/kg Fourth cohort enrollment underway Company to hold conference call at 8:30am ET today SAN DIEGO, June 24, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "R
6/24/24 7:00:00 AM ET
$RGLS
Biotechnology: Pharmaceutical Preparations
Health Care
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Mechanistic dose response observed at a 2mg/kg dose level based on urinary biomarker analyses Encouraging exploratory results of imaging-based biomarkers with greatest reductions in total kidney volume seen in patients with the highest increases in PC1 and PC2 Cohort 3 fully enrolled with data readout anticipated in mid-2024; Cohort 4 screening to start in 2Q 2024 Company to hold conference call at 8:30am ET today SAN DIEGO, March 12, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced positive topline results from the second
3/12/24 6:30:00 AM ET
$RGLS
Biotechnology: Pharmaceutical Preparations
Health Care
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Statistically significant increase in urinary polycystin 1(PC1) after treatment with RGLS8429 Urinary polycystin exhibits anticipated pharmacokinetics/pharmacodynamics (PK/PD) correlation in patients with ADPKD Company to hold conference call at 8:30 a.m. EDT today SAN DIEGO, Sept. 20, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced positive topline results from the first cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD.
9/20/23 7:00:00 AM ET
$RGLS
Biotechnology: Pharmaceutical Preparations
Health Care

Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
First patient dosed in second cohort of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 R&D Day to discuss our ADPKD program to be held Wednesday, September 6th Strengthened leadership through appointments of Preston S. Klassen, M.D. as President and Head of Research & Development and Curtis A. Monnig, Ph.D. as Vice President of CMC SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results and provided a corporate upd
8/8/23 4:05:00 PM ET
$RGLS
Biotechnology: Pharmaceutical Preparations
Health Care
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors
SAN DIEGO, June 23, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced Preston S. Klassen, M.D., President and Head of Research & Development, has been appointed to the Company's Board of Directors. "We are delighted to have Dr. Klassen join our board during this exciting time for Regulus, as we advance the clinical development of RGLS8429 for the treatment of ADPKD," said Stelios Papadopoulos, Ph.D., Chairman
6/23/23 8:00:00 AM ET
$RGLS
Biotechnology: Pharmaceutical Preparations
Health Care
Regulus Therapeutics Strengthens Research & Development Leadership
Appoints Preston S. Klassen, M.D., as President and Head of Research & Development Curtis A. Monnig, Ph.D., named Vice President of CMC SAN DIEGO, June 12, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment of Preston S. Klassen M.D., M.H.S., to President and Head of Research and Development. Dr. Klassen brings over 20 years of experience in leadership roles in both large and small biopharmaceutical companies. In addition, the Company announced the appointment of Curtis A. Monnig, Ph.D., to Vice President of
6/12/23 7:59:58 AM ET
$RGLS
Biotechnology: Pharmaceutical Preparations
Health Care

Regulus Therapeutics Announces Expected Addition To The Russell 3000 And Russell 2000 Indexes

Chat with this insight

Recent Analyst Ratings for $RGLS

$RGLS Press Releases

Fastest customizable press release news feed in the world

Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

$RGLS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Oppenheimer initiated coverage on Regulus Therapeutics with a new price target

Leerink Partners initiated coverage on Regulus Therapeutics with a new price target

Cantor Fitzgerald initiated coverage on Regulus Therapeutics with a new price target

$RGLS SEC Filings

SEC Form 10-Q filed by Regulus Therapeutics Inc.

Regulus Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

SEC Form 8-K filed by Regulus Therapeutics Inc.

$RGLS Financials

Live finance-specific insights

Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

$RGLS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Collier Kathryn J bought $7,280 worth of shares (4,000 units at $1.82), increasing direct ownership by 146% to 6,740 units (SEC Form 4)

SEC Form 4 filed by Rastetter William H

SEC Form 4 filed by Papadopoulos Stelios

$RGLS Leadership Updates

Live Leadership Updates

$RGLS Market Insights

Live Market Insights

$RGLS Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates

Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors

Regulus Therapeutics Strengthens Research & Development Leadership

HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $10 Price Target

Canaccord Genuity Maintains Buy on Regulus Therapeutics, Raises Price Target to $28

Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday

Director Collier Kathryn J bought $7,280 worth of shares (4,000 units at $1.82), increasing direct ownership by 146% to 6,740 units (SEC Form 4)

$RGLS Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Regulus Therapeutics Inc.

SEC Form SC 13G filed by Regulus Therapeutics Inc.

SEC Form SC 13G/A filed by Regulus Therapeutics Inc. (Amendment)

Recent Analyst Ratings for
$RGLS

$RGLS
Press Releases

$RGLS
Analyst Ratings

$RGLS
SEC Filings

$RGLS
Financials

$RGLS
Insider Trading

$RGLS
Leadership Updates

$RGLS
Market Insights

$RGLS
Insider Purchases

$RGLS
Large Ownership Changes